Small Interfering RNA Market Trends

Growth Drivers

Rising Popularity of Personalized Medicine – Small interfering RNA (siRNA) has emerged as a promising possibility for precision therapy in cancer and other diseases as it is highly specific and can be easily generated for multiple target genes.
Growing Geriatric Population- The elderly population is more susceptible to several age-related diseases such as Alzheimer's disease, Huntington's disease, and Parkinson's disease which may benefit from SiRNA treatment.According to estimates, the proportion of the world's population over 60 years old is anticipated to treble from roughly 11 to more than 22% by 2050.

Challenges

High Cost of Developing SiRNA Therapies - Despite their appealing method of action, small interfering RNA therapies confront several hurdles as they are often generated using chemical synthesis, which can be costly if large quantities are required.
Stringent Regulations to Obtain Approvals for SiRNA Therapies
Development of Effective Delivery Methods Can be Challenging

Small Interfering RNA Market: Key Insights

Base Year	2023
Forecast Year	2024-2036
CAGR	~18.5%
Base Year Market Size (2023)	~ USD 67 Billion
Forecast Year Market Size (2036)	~ USD 13 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

Rising cases of cancer across the globe and the growing partnerships and collaborations are the major factors driving the growth of the market.

The market size of small interfering RNA is anticipated to attain a CAGR of 18.5% over the forecast period, i.e., 2024-2036.

The major players in the market are Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, AInylam Pharmaceuticals, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health

The liposome based systemic therapy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Small Interfering RNA Market Trends